1. Home
  2. CLPT vs AKBA Comparison

CLPT vs AKBA Comparison

Compare CLPT & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ClearPoint Neuro Inc.

CLPT

ClearPoint Neuro Inc.

HOLD

Current Price

$11.57

Market Cap

353.5M

Sector

Health Care

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.01

Market Cap

375.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLPT
AKBA
Founded
1998
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
353.5M
375.0M
IPO Year
2009
2014

Fundamental Metrics

Financial Performance
Metric
CLPT
AKBA
Price
$11.57
$1.01
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$20.00
$4.67
AVG Volume (30 Days)
496.1K
5.0M
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
93.94
EPS
N/A
N/A
Revenue
$36,971,000.00
N/A
Revenue This Year
$45.67
N/A
Revenue Next Year
$19.51
N/A
P/E Ratio
N/A
N/A
Revenue Growth
17.78
N/A
52 Week Low
$8.27
$0.88
52 Week High
$30.10
$4.08

Technical Indicators

Market Signals
Indicator
CLPT
AKBA
Relative Strength Index (RSI) 51.09 34.96
Support Level $10.09 N/A
Resistance Level $11.73 $1.56
Average True Range (ATR) 0.96 0.08
MACD -0.11 -0.03
Stochastic Oscillator 28.17 19.55

Price Performance

Historical Comparison
CLPT
AKBA

About CLPT ClearPoint Neuro Inc.

ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: